Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient

Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.

• Source: Shutterstock

Sanofi could try to differentiate Zantac 360 among histamine-2 blockers in the OTC heartburn remedy category by qualifying and modifying its “#1 doctor recommended” claim that an industry self-regulation group’s appeals panel says it didn’t support.

The French firm asked BBB National Programs Inc.’s National Advertising Review Board to consider using a claim of “#1 doctor...

Welcome to HBW Insight

Create an account to read this article

More from Marketing & Advertising

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Scope Launches Eyelid-Friendly Eye Cream In The UK

 
• By 

Eyelids have the "thinnest, most sensitive skin on the body" and are "highly prone to dehydration," which is why Scope has launched new Optase Life Sensitive Eye Daily Renewal Cream.

P&G’s Crest Gum Detoxify Ad Claims Rinsed Clean In NAD Review On GuruNanda Challenge

 

P&G provided sufficient support for all challenged claims, including the “Gum Detoxify” brand used on the product label and in advertising on the website and in magazine detail pages.

German Associations Call For EU Green Claims Directive Trilogue Suspension

 
• By 

Pharma Deutschland is one of 21 German associations calling for trilogue negotiations in relation to the EU Green Claims Directive to be suspended while a “comprehensive and independent written impact assessment” is undertaken.

More from Business

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By 

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

 
• By 

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.

Reckitt Strikes Deal To Sell Essential Home Unit To Focus On CHC, Hygiene

 
• By 

Advent International is poised to take control of Reckitt's Essential Home business, but the UK-based firm will retain a 30% stake.